SCHEMBL5463193

SCHEMBL5463193

Cc1c(N)cccc1OCCN1CCCC1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.63
LTA4H P09960 1/20 0.58
POLB P06746 1/20 0.57
CYP2D6 P10635 2/20 0.55
CYP2C19 P33261 2/20 0.55
CYP1A2 P05177 1/20 0.55
HSD17B10 Q99714 1/20 0.55
TSHR P16473 1/20 0.54
SMN1; SMN2 Q16637 3/20 0.51
HTR1A P08908 1/20 0.51
HRH1 P35367 3/20 0.50
DRD1 P21728 2/20 0.50
DRD4 P21917 2/20 0.50
DRD5 P21918 2/20 0.50
DRD3 P35462 2/20 0.50
DRD2 P14416 1/20 0.49
KDM4E B2RXH2 1/20 0.49
ALDH1A1 P00352 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
HTT P42858 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3725632 0.87 SMN1; SMN2 (0.64) POLBCYP2D6TSHRSMN1; SMN2HTR1A
SCHEMBL14410108 0.84 TDP1 (0.77) TDP1POLBCYP2D6CYP2C19CYP1A2
SCHEMBL30150794 0.84 LTA4H (0.73) TDP1LTA4HPOLBCYP2D6CYP2C19
SCHEMBL1031593 0.84 LTA4H (0.73) TDP1LTA4HPOLBCYP2D6CYP2C19
SCHEMBL1027777 0.83 LTA4H (0.71) TDP1LTA4HPOLBCYP2D6CYP2C19
SCHEMBL12586924 0.82 ALDH1A1 (0.62) TDP1LTA4HPOLBCYP2D6CYP2C19
SCHEMBL13744815 0.82 POLB (0.70) TDP1LTA4HPOLBCYP2D6CYP2C19
SCHEMBL30670120 0.81 TDP1 (0.61) TDP1POLBCYP2D6CYP2C19CYP1A2
SCHEMBL8264564 0.78 TDP1 (1.00) TDP1POLBCYP2D6CYP2C19CYP1A2
SCHEMBL24445406 0.77 CYP2D6 (0.68) TDP1CYP2D6CYP2C19CYP1A2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070161677-A1 Bisarylurea derivatives MERCK PATENT GMBH (DE) 2007-07-12 US disclosed
US-20070161677-A1 Bisarylurea derivatives MERCK PATENT GMBH (DE) 2007-07-12 US disclosed
US-20070054888-A1 NOVEL SUBSTITUTED DIAMINE DERIVATIVES USEFUL AS MOTILIN AGONISTS ORTHO-MCNEIL PHARMACEUTICAL, INC. 2007-03-08 US disclosed
US-7166601-B2 Substituted diamine derivatives useful as motilin antagonists ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2007-01-23 US disclosed
US-7112586-B2 Substituted diamine derivatives useful as motilin antagonists ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2006-09-26 US disclosed
US-20060183741-A1 Treatment of associated conditions and disorders such as gastrointestinal reflux disorders, eating disorders leading to obesity and irritable bowel syndrome JOHNSON SIGMOND G 2006-08-17 US disclosed
US-6967199-B2 Substituted diamine derivatives useful as motilin antagonists ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2005-11-22 US disclosed
US-20050148584-A1 Novel substituted diamine derivatives useful as motilin antagonists JOHNSON SIGMOND G (US) 2005-07-07 US disclosed
US-20030203906-A1 A phenylamide derivatives for treating gastrointestinal reflux disorders, eating disorder obesity and irritable bowel disorder JOHNSON SIGMONG G (US) 2003-10-30 US disclosed
EP-1294695-A2 SUBSTITUTED DIAMIDE DERIVATIVES USEFUL AS MOTILIN ANTAGONISTS Ortho-McNeil Pharmaceutical, Inc. (US) 2003-03-26 EP disclosed
US-6511980-B2 For therapy of gastrointestinal reflux disorders, eating disorders leading to obesity and irritable bowel disorder ORTHO MCNEIL PHARMACEUTICAL, INC. 2003-01-28 US disclosed
US-20020013352-A1 For therapy of gastrointestinal reflux disorders, eating disorders leading to obesity and irritable bowel disorder ORTHO-MCNEIL PHARMACEUTICAL, INC. 2002-01-31 US disclosed
WO-2001085694-A2 SUBSTITUTED DIAMIDE DERIVATIVES USEFUL AS MOTILIN ANTAGONISTS ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2001-11-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161677-A1 Bisarylurea derivatives BRAF, RAF1, NRAS TDP1 835/4885LTA4H 4652/4885POLB 919/4885
US-20070054888-A1 NOVEL SUBSTITUTED DIAMINE DERIVATIVES USEFUL AS MOTILIN AGONISTS MLNR, NPY4R, GIPR TDP1 3352/4885LTA4H 1811/4885POLB 4322/4885
US-20020013352-A1 For therapy of gastrointestinal reflux disorders, eating disorders leading to obesity and irritable bowel disorder MLNR, GIPR, NPY1R TDP1 3553/4885LTA4H 2264/4885POLB 4511/4885
US-20060183741-A1 Treatment of associated conditions and disorders such as gastrointestinal reflux disorders, eating disorders leading to obesity and irritable bowel syndrome MLNR, NPY4R, GIPR TDP1 3743/4885LTA4H 1628/4885POLB 4518/4885
US-20030203906-A1 A phenylamide derivatives for treating gastrointestinal reflux disorders, eating disorder obesity and irritable bowel disorder MLNR, GIPR, NPY1R TDP1 3434/4885LTA4H 2663/4885POLB 4504/4885
US-20050148584-A1 Novel substituted diamine derivatives useful as motilin antagonists MLNR, NPY4R, GIPR TDP1 3578/4885LTA4H 2168/4885POLB 4251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.